Germany's crumbling bridges need additional funds, auditors say
BERLIN (Reuters) - Germany is lagging on its targets to renovate the country's dilapidated bridges by 2032 and needs to boost investment, according to auditors, who said the government's goals appear unachievable.
Only 69 of the 280 structures scheduled for renovation in 2024 under the 2032 plan had been modernised, Germany's federal audit office said.
To achieve the target, Autobahn GmbH, which is in charge of the renovations, would have to modernise around 590 substructures every year from now on. "That doesn't seem realistic," Kay Scheller, president of the office, said.
"The gap between planned and successful modernisation will continue to widen over the years," she said.
The audit office, which accused the transport ministry of presenting progress too positively and of falling short on the targets, said a total of 2.1 billion euros ($2.39 billion) would be required for 400 substructures in 2026, while the ministry put the sum at 1.4 billion euros.
The transport ministry disagrees with this assessment of "embellishing" the numbers, noting that the modernisation of bridges is a top priority, a spokesperson for the ministry told Reuters.
"The implementation of the programme is on schedule and is communicated transparently by the transport ministry and Autobahn GmbH," the spokesperson said.
The German auditors demanded more funds for the government-owned Autobahn GmbH without giving an exact figure, as that depends on construction price developments.
($1 = 0.8788 euros)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Zelensky announces updated Ukrainian delegation list, ahead of planned peace talks with Russia
President Volodymyr Zelensky announced on June 1 an updated 14-member Ukrainian delegation for upcoming peace talks with Russia in Istanbul, expanding the original group of 12. Defense Minister Rustem Umerov will again lead the delegation, which will include several new figures from Ukraine's military, human rights, and legal sectors. Three officials – Andrii Fomin, Yurii Kovbasa, and Yevhenii Ostrianskyi – are participating for the first time, while Oleksii Malovatskyi, involved in the May 16 talks, will not join. The meeting is scheduled to take place on June 2, with both Russian and Ukrainian delegations expected to attend. Also, security advisors from the U.S., U.K., France, and Germany plan to attend, according to U.S. President Donald Trump's special envoy for Ukraine, Keith Kellogg. Russia has not officially submitted its memorandum outlining peace terms, but Ukraine plans to present a detailed roadmap aimed at securing a lasting settlement. According to the proposal, the process would begin with a minimum 30-day ceasefire, followed by a full exchange of prisoners and the return of Ukrainian children taken to Russian-held areas, ultimately leading to a potential meeting between Zelensky and Putin. The plan was reported on June 1 by Reuters, which reviewed a copy of the document. While the U.S. and Ukraine have pushed for an unconditional ceasefire, the Kremlin has rejected it. Instead, Moscow has regularly voiced maximalist demands that are unlikely to be accepted by Kyiv, such as recognition of Russia's illegal annexation of Ukrainian regions and withdrawal of Ukrainian troops from the parts of these regions remaining under Kyiv's control. Trump has expressed frustration with Russia's reluctance to make concessions and its intensifying and deadly attacks on Ukraine. However, he has so far refused to sanction Russia. The talks are tentatively still set to continue on June 2, though Russia has not officially commented yet, following Ukraine's Security Service's (SBU) major intelligence drone operation earlier today. The drones destroyed 41 Russian bombers at four airfields across Russia, in what Kyiv called a long-planned blow to Moscow's strike capabilities. Read also: Officials from US, UK, France, Germany to attend Ukraine-Russia peace talks, Kellogg says We've been working hard to bring you independent, locally-sourced news from Ukraine. Consider supporting the Kyiv Independent.
Yahoo
21 minutes ago
- Yahoo
US asks Australia to increase defense spending to 3.5% of GDP
WASHINGTON (Reuters) -U.S. Defense Secretary Pete Hegseth asked Australia to increase its defense spending to 3.5% of gross domestic product during a meeting with Australian Defense Minister Richard Marles, the Pentagon said on Sunday. The defense chiefs also discussed security issues including accelerating U.S. defense capabilities in Australia, advancing defense industrial base cooperation and creating supply chain resilience, the Defense Department said in a statement. "On defense spending, Secretary Hegseth conveyed that Australia should increase its defense spending to 3.5 percent of its GDP as soon as possible," the statement said. The ministers' meeting on Friday on the sidelines of the Shangri-La Dialogue, Asia's premier security forum, is only the second between the security allies since U.S. President Donald Trump took office in January. Marles said after the meeting they did not discuss a specific percentage of GDP to raise Australian defense spending.
Yahoo
40 minutes ago
- Yahoo
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk
By Julie Steenhuysen CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts said on Sunday. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumor growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56% reduction in the risk of disease progression or death, said Dr. Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3,256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as estrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40% of patients treated with aromatase inhibitors develop mutations in the estrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective estrogen receptor degraders, or SERDS, block estrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to look for ESR1 mutations until 315 patients were identified. They were randomly assigned to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr. Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice. THE FUTURE OF CANCER TREATMENT AstraZeneca Chief Executive Pascal Soriot in a press briefing acknowledged that monitoring patients for drug resistance before cancer progresses would require a switch in practice, but said it represents the future of cancer treatment. "It will be complicated in the beginning," he said, "but over time, like everything else, we will manage to simplify it and it will become part of what people do." In a separate trial, adding AstraZeneca's immunotherapy Imfinzi to standard treatment before and after surgery in patients with early-stage stomach and esophageal cancers helped delay cancer progression or recurrence compared to chemotherapy alone. The global study of nearly 950 patients tested Imfinzi, known chemically as durvalumab, in combination with a chemotherapy regimen called FLOT given around the time of initial cancer surgery. The durvalumab plus FLOT combination led to a 29% reduction in disease recurrence, progression or death, referred to as event-free survival, compare with those who received the chemotherapy regimen alone. "We demonstrate that immunotherapy works in early-stage disease, which is great," lead study author Dr. Yelena Janjigian of Memorial Sloan Kettering Cancer Center in New York told reporters at the meeting. "We did not see any new safety signals, so this will change practice for our patients, which is exciting to see." Both studies were also published on Sunday in the New England Journal of Medicine.
